Login to Your Account



In The Clinic NEWS
AAN 2015
The ginormous 67th American Academy of Neurology (AAN) annual meeting is in full swing, with more than 2,500 abstracts scheduled for presentation at scientific sessions during the week.

On the heels of last summer's phase IIb failure of TC-5214 in overactive bladder and a string of other duds with neuronal nicotinic receptors, Targacept Inc. said top-line results from a phase I/II exploratory study of TC-6499 as a treatment for diabetic gastroparesis also missed its primary endpoint and the program will be discontinued.

It might not add much to Pfizer Inc.'s bottom line, since oral Ibrance (palbociclib) is approved already as a first-line therapy, but the first randomized phase III data with the compound made a strong showing in the trial called PALOMA-3.
More In The Clinic Headlines

Cast Your Vote

Has biotech’s bubble burst?: